Compounds and methods for treating inflammatory disorders
2C compounds with targeted 5-HT 2A receptor activity provide effective anti-inflammatory treatment for disorders like asthma and rheumatoid arthritis, addressing the need for small molecule therapies that avoid CNS side effects.
Patent Information
- Application Number
- JP2021559994
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-12
- Filing Date
- 2020-04-13
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-04-13
AI Technical Summary
Current treatments for inflammatory disorders, such as those targeting TNF-α signaling, lack effective small molecule anti-inflammatory compounds that can manage aberrant inflammatory signaling without inducing undesirable central nervous system effects.
Development of compounds with specific structures, such as 2C compounds, which have high anti-inflammatory efficacy while minimizing behavioral effects by targeting the 5-HT 2A receptor, along with their pharmaceutically acceptable salts and prodrugs, formulated for various routes of administration.
The 2C compounds effectively treat inflammatory disorders like asthma and rheumatoid arthritis with minimal psychoactive side effects, maintaining therapeutic efficacy at low circulating drug plasma levels and specific dosing frequencies.
Smart Images

Figure 0007596296000033 
Figure 0007596296000034 
Figure 0007596296000035
Abstract
Description
[Technical field]
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 833,140, filed April 12, 2019, the entire contents of which are incorporated herein by reference in their entirety.
[0002] FIELD OF THEINVENTION In general, the invention features compositions and methods for treating inflammatory disorders. [Background technology]
[0003] 2. Background of the Invention Inflammation is a natural and necessary physiological process that occurs when an organism is exposed to foreign stimuli such as pathogens. However, inflammatory signaling can occasionally be misdirected and occur in the absence of a legitimate threat to the organism. Such aberrant inflammatory signaling can damage host cell tissues and may lead to a variety of long-term complications. Currently, major pathways of inflammation, such as TNF-α signaling, are targeted using biologic agents such as monoclonal antibodies (infliximab and adalimumab) and soluble TNF-α receptors (etanercept).
[0004] However, there remains a need in the art for the development of small molecule anti-inflammatory compounds, for example, for the treatment of inflammatory conditions. Summary of the Invention
[0005] The present invention discloses compounds and pharmaceutical compositions with potent anti-inflammatory properties.Methods of using the compounds or compositions of the present invention are also provided, for example, for treating inflammatory disorders in subjects in need of such treatment.
[0006] One aspect of the present invention is a compound of formula (X) or a pharma- ceutically acceptable acid addition salt (e.g., hydrochloride) or prodrug thereof, wherein R' can be H or CH3 and R'' can be H or CH3. In certain embodiments, R' can be H. In other embodiments, R' can be CH3 (e.g., in the R stereochemistry). In some embodiments, R'' can be H. In still further embodiments, R is a small branched alkyl group (e.g., -CH(CH3)2, -C(CH3)3, or -CH(CH2)2), In some embodiments, R may be TIFF0007596296000003.tif17128, which may be substituted with one or more CH3 groups, including all stereoisomers TIFF0007596296000004.tif38140. In some embodiments, R is TIFF0007596296000005.tif7128, which may be substituted with one or more CH3 groups, including all stereoisomers TIFF0007596296000006.tif35159.
[0007] One aspect of the present invention is a compound of formula (Y) or a pharma- ceutically acceptable acid addition salt (e.g., hydrochloride) or prodrug thereof, wherein R is CH(CH3)2, C(CH3)3, CH(CH2)2), It could be TIFF0007596296000008.tif19128.
[0008] In one aspect, the present invention provides a compound of formula (I) TIFF0007596296000009.tif36128 or a pharma- ceutically acceptable acid addition salt (e.g., hydrochloride) or prodrug thereof.
[0009] In another aspect, the present invention provides a compound of formula (II) TIFF0007596296000010.tif41128 or a pharma- ceutically acceptable acid addition salt (e.g., hydrochloride) or prodrug thereof.
[0010] In yet another aspect, the present invention provides a compound of formula (III) TIFF0007596296000011.tif41128 or a pharma- ceutically acceptable acid addition salt (e.g., hydrochloride) or prodrug thereof.
[0011] In another aspect, the invention includes a composition of any of the preceding aspects (e.g., a compound of Formula (I), (II), or (III)) or an acid addition salt or prodrug thereof and a pharma- ceutically acceptable excipient. Such pharmaceutical compositions can be formulated for oral, intranasal, or pulmonary administration.
[0012] In another aspect, provided herein is a method of treating an inflammatory disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition of any of the preceding aspects. In some embodiments, the compound is administered to a subject in need thereof to maintain a circulating drug plasma level of less than 20 ng / mL (e.g., 0.05 to 20 ng / mL, e.g., 0.1 to 15 ng / mL, 0.5 to 10 ng / mL, or 1 to 5 ng / mL, e.g., 0.05 to 0.1 ng / mL, 0.1 to 0.2 ng / mL, 0.2 to 0.3 ng / mL, 0.3 to 0.4 ng / mL, 0.4 to 0.5 ng / mL, 0.5 to 1.0 ng / mL). , 1.0-5ng / mL, 5-10ng / mL, 10-15ng / mL, or 15-20ng / mL, for example, about 0.05ng / mL, 0.1ng / mL, 0.2ng / mL, 0.5ng / mL, 1.0ng / mL, 2.0ng / mL, 2.5ng / mL, 5.0ng / mL, 7.5ng / mL, 10ng / mL, 12ng / mL, 15ng / mL, or 20ng / mL. In some embodiments, the circulating drug plasma level of the compound is below the detection limit (e.g., 0.1ng / mL or less). In some embodiments, the amount of the compound administered is 20 μg / kg body weight or less (e.g., less than 20 μg / kg, less than 15 μg / kg, less than 10 μg / kg, or less than 5 μg / kg body weight). body weight, e.g., 1-20 μg / kg body weight, e.g., 1-5 μg / kg, 5-10 μg / kg, 10-15 μg / kg, or 15-10 μg / kg, e.g., about 5 μg / kg, about 10 μg / kg, about 15 μg / kg, or about 20 μg / kg. In some embodiments, the compound is administered once or more per week (e.g., once per week, twice per week, three times per week, four times per week, five times per week, six times per week, seven times per week, or more, e.g., once per day, twice per day, three times per day, etc.). In some embodiments, the compound is administered intermittently, e.g., every other day, every other week, once per month, etc.
[0013] In some embodiments of any of the preceding embodiments or any of the methods described herein, the inflammatory disorder is asthma, chronic obstructive pulmonary disease, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, sepsis, or conjunctivitis.
[0014] In any of the methods provided herein, the compound can be administered by any suitable route of administration, for example, orally, intranasally, or by inhalation. In some embodiments, the compound of the present invention or a pharmaceutical composition thereof is administered by one or more of a variety of routes, including nasal, buccal, oral, inhalation (e.g., as an oral spray, nebulizer, nasal spray, or aerosol), intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intracerebroventricular, transdermal, intradermal, rectal, intravaginal, intraperitoneal, topical (e.g., by powder, ointment, cream, gel, lotion, and / or drops), mucosal, intestinal, vitreous, intratumoral, sublingual, intratracheal instillation, bronchial instillation, and / or via a portal vein catheter. In some embodiments, the composition is administered by systemic intravenous injection. In certain embodiments, the composition is administered intravenously and / or orally.
[0015] definition In order to facilitate the understanding of the present invention, some terms are defined below and throughout this disclosure.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Terms in this specification are used to describe certain embodiments of the present invention, but their usage does not limit the present invention, except as outlined in the claims.
[0016] As used herein, "acid addition salt" refers to any pharma- ceutically acceptable salt.
[0017] The term "prodrug" as used herein refers to the inactive precursor form of a pharmacologic active substance that can be enzymatically activated or converted into a more active parent form.See, for example, Wilman, "Prodrugs in Cancer Chemotherapy" Biochemical Society Transactions, 14, pp.375-382, 615th Meeting Belfast (1986) and Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery," Directed Drug Delivery, Borchardt et al., (ed.), pp.247-267, Humana Press (1985).
[0018] As used herein, the term "pharmaceutical acceptable carrier" refers to an excipient or diluent in a pharmaceutical composition. For example, a pharmaceutical acceptable carrier can be a vehicle that can suspend or dissolve an active compound (e.g., a composition described herein). A pharmaceutical acceptable carrier must be compatible with other ingredients of the formulation and not harmful to the recipient. In the present disclosure, a pharmaceutical acceptable carrier must provide suitable pharmaceutical stability for the compound described herein. The nature of the carrier will vary depending on the mode of administration.
[0019] As used herein, the term "treat" or "treating" refers to the administration of a compound or pharmaceutical composition for therapeutic purposes. "Treating a disorder" or use for "therapeutic treatment" refers to administering a treatment to a patient already suffering from a disease to ameliorate the disease or one or more symptoms thereof and improve the patient's condition (e.g., by reducing one or more symptoms of inflammation). The term "therapeutic" includes the effect of reducing the deleterious clinical effects of a particular inflammatory process (i.e., the consequences of inflammation, not the symptoms of inflammation). The methods of the present invention can be used as a primary preventative measure, i.e., to prevent a condition or to reduce the risk of developing a condition. Prevention refers to the prophylactic treatment of a patient who may not have fully developed a condition or disorder, but who is susceptible to or otherwise at risk for the condition. Thus, in the claims and embodiments, the methods of the present invention can be used for either therapeutic or prophylactic purposes.
[0020] The term "administration" or "administering" refers to a method of providing a dosage of a compound or pharmaceutical composition to a subject.
[0021] The term "therapeutically effective amount" as used herein refers to an amount, e.g., a pharmaceutical dose, effective in inducing a desired effect in a subject or in treating a subject having a condition or disorder (e.g., inflammatory disorder) as described herein. It is also understood that "therapeutically effective amount" as used herein can be interpreted as an amount that provides a desired therapeutic and / or prophylactic effect, taken in one or more doses or any dosage or route, and / or taken alone or in combination with other therapeutic agents. For example, in the context of administering a composition as described herein used for treating a disorder or condition, an effective amount of a compound is an amount sufficient to prevent, slow down, or reverse the progression of a disorder or condition, e.g., as compared to the response obtained without administration of the compound.
[0022] Terms such as "a," "an," "the," and the like are not intended to refer to a singular entity only, but also include a general class of which a particular example can be used for illustration.
[0023] As used herein, the term "about" refers to a value within 10% above or below the stated value. [The present invention 1001] Compounds of formula (I) TIFF0007596296000012.tif49128 or a pharma- ceutically acceptable acid addition salt or prodrug thereof. [The present invention 1002] A pharmaceutical composition comprising a compound of the present invention and a pharma- ceutically acceptable excipient. [The present invention 1003] The pharmaceutical composition of the present invention 1002, which is formulated for oral, intranasal, or pulmonary administration. [The present invention 1004] A method for treating an inflammatory disorder in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the present invention 1001 or a pharmaceutical composition of the present invention 1002 or 1003. [The present invention 1005] The method of claim 1004, wherein said compound is administered in an amount of less than 20 μg / kg body weight. [The present invention 1006] The method of any one of claims 1004 to 1005, wherein said compound is administered at a frequency of 1 to 3 times per week. [The present invention 1007] The method of any of claims 1004 to 1006, wherein said inflammatory disorder is selected from the group consisting of asthma, chronic obstructive pulmonary disease, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, sepsis, and conjunctivitis. [The present invention 1008] The method of any of claims 1004 to 1007, wherein said compound is administered orally, intranasally, or by inhalation. [The present invention 1009] Compound of formula (II) TIFF0007596296000013.tif47128 or a pharma- ceutically acceptable acid addition salt or prodrug thereof. [The present invention 1010] A pharmaceutical composition comprising a compound of the present invention and a pharma- ceutically acceptable excipient. [The present invention 1011] The pharmaceutical composition of the present invention 1010 formulated for oral, intranasal, or pulmonary administration. [The present invention 1012] A method for treating an inflammatory disorder in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the present invention 1009 or a pharmaceutical composition of the present invention 1010 or 1011. [The present invention 1013] The method of claim 10, wherein the compound is administered in an amount of less than 20 μg / kg body weight. [The present invention 1014] The method of any one of claims 1012 to 1013, wherein the compound is administered one to three times a week. [The present invention 1015] Any of the methods of claims 1012 to 1014, wherein the inflammatory disorder is selected from the group consisting of asthma, chronic obstructive pulmonary disease, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, sepsis, and conjunctivitis. [The present invention 1016] The method of any of claims 1012 to 1015, wherein said compound is administered orally, intranasally, or by inhalation. [The present invention 1017] Compound of formula (III) TIFF0007596296000014.tif44128 or a pharma- ceutically acceptable acid addition salt or prodrug thereof. [The present invention 1018] A pharmaceutical composition comprising a compound of the present invention and a pharma- ceutically acceptable excipient. [The present invention 1019] A pharmaceutical composition of the present invention 1018 formulated for oral, intranasal, or pulmonary administration. [The present invention 1020] A method for treating an inflammatory disorder in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of the present invention 1017 or a pharmaceutical composition of the present invention 1018 or 1019. [The present invention 1021] The method of claim 1020, wherein the compound is administered in an amount of less than 20 μg / kg body weight. [The present invention 1022] The method of any one of claims 1020 to 1021, wherein said compound is administered at a frequency of 1 to 3 times per week. [The present invention 1023] The method of any of claims 1020 to 1022, wherein the inflammatory disorder is selected from the group consisting of asthma, chronic obstructive pulmonary disease, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, sepsis, and conjunctivitis. [The present invention 1024] The method of any of claims 1020 to 1023, wherein said compound is administered orally, intranasally, or by inhalation. [Brief description of the drawings]
[0024] The following drawings are illustrative of certain embodiments of the present invention and are not intended to be limiting of the various embodiments encompassed by the present invention.
[0025] [Figure 1A] 1 is a schematic diagram showing the synthesis of 2,5-dimethoxy-4-isobutylphenethylamine (2C-iBu). [Figure 1B-1] 1 is a series of graphs showing the liquid chromatography-UV (LCUV) profile of 2C-iBu. [Figure 1B-2] See legend to Figure 1B-1. [Figure 1C-1]1 is a series of graphs showing the liquid chromatography-mass spectrometry (LCMS) profile of 2C-iBu. [Figure 1C-2] See legend to Figure 1C-1. [Figure 1C-3] See legend to Figure 1C-1. [Figure 2A] 2A-2G are a series of graphs showing the change in enhanced pause (ΔPenh) as a function of methacholine challenge in adult male Brown Norway rats, the details of which are described in Example 3. Rats were either untreated (naive, circles), treated with ovalbumin (OVA, squares), or treated with various experimental compounds in combination with OVA (triangles). Experimental compounds included 1.0 mg / kg R-DOI (FIG. 2A, *p<0.05, significant difference from OVA to naive, #p<0.05 OVA vs. OVA+R-DOI), 1.0 mg / kg 25-I-NBOMe (Fig. 2B, *p<0.05, significant difference from OVA to naïve, #p<0.05, significant difference from OVA to OVA+25-I-NBOMe, ^p<0.05, significant difference from OVA+25-I-NBOMe to naïve), 1.0 mg / kg DOB (Fig. 2C, #p<0.05, significant difference from OVA to OVA+DOB, *p<0.05, significant difference from OVA to naïve, ^p<0.05, significant difference from OVA+DOB to naïve), 0.5 mg / kg 2C-B-Fly.HCl (Fig. 2D, *p p<0.05, significant difference from OVA to naïve, and significant difference from 2C-B-Fly.HCl+OVA to naïve), 0.5 mg / kg 2CB2 (Figure 2E, #p<0.05, significant difference from OVA to OVA+TCB2, *p<0.05, significant difference from OVA to naïve, ^p<0.05, significant difference from OVA+TCB2 to naïve), 0.5 mg / kg DOTFM (Figure 2F, ^p<0.05, significant difference from OVA+DOTFM to naïve), and 2C-iBu (Figure 2G, *p<0.05, significant difference from OVA+2C-iBu.HCl to naïve). The structure of each experimental compound is shown to the left of the corresponding graph. [Figure 2B] See legend to Figure 2A. [Figure 2C] See legend to Figure 2A. [Figure 2D] See legend to Figure 2A. [Figure 2E] See legend to Figure 2A. [Figure 2F] See legend to Figure 2A. [Figure 2G] See legend to Figure 2A. [Diagram 3] Structure-activity relationship table summarizing the functional properties of various DOx and 2C compounds. *: not effective (-), moderately effective (+), very effective (++); **: data based on literature search performed in January 2019; (NT) not tested; (NR) not reported, i.e., insufficient publicly available property data. [Figure 4] FIG. 13 is a dose-response curve showing % inhibition of ΔPenh as a function of 2C-iBu concentration in a rat OVA allergic asthma model. [Diagram 5] FIG. 5A is a graph showing the effect of R-DOI on head twitch response (HTR). Data are presented as group means ± SEM across the 30 min test session. Drug dose refers to equivalent free base weight. **p<0.01, significant difference from vehicle control group (Tukey's test). FIG. 5B is a graph showing the results of a time course study of HTR induced by R-DOI. Data are presented as group means ± SEM during 2 min time blocks. Drug dose refers to equivalent free base weight. [Figure 6] FIG. 6A is a graph showing the effect of 2C-iBu on HTR. Data are presented as group means ± SEM across the 30 min test session. Drug dose refers to equivalent free base weight. *p<0.05, **p<0.01, significant difference from vehicle control group (Tukey's test). FIG. 6B is a graph showing the results of a time course study of HTR induced by 2C-iBu. Data are presented as group means ± SEM during 2 min time blocks. Drug dose refers to equivalent free base weight. [Figure 7]Graph showing the results of a time course study of HTR induced by 1.0 mg / kg R-DOI and 3.0 mg / kg 2C-iBu. Data are presented as group mean ± SEM during 5 min time blocks. Drug doses refer to equivalent free base weight. *p<0.01, significant difference between groups (Sidak's multiple comparison test). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] Detailed Description of the Invention The present invention relates to 2C compounds having the structures of formulas (I), (II), and (III): TIFF0007596296000015.tif160128 and acid addition salts and prodrugs thereof. Also provided herein are pharmaceutical compositions comprising the 2C compounds, and methods of treatment using the compounds and pharmaceutical compositions, e.g., methods of treating an inflammatory disorder in a subject in need thereof.
[0027] I. Compound Phenethylamine hallucinogens include compounds that have an amphetamine structure with an alpha methyl in the side chain of the main ring. This class of compounds is called DOx, the structure of which is shown below, where R can be any suitable group (e.g., methyl, iodine, ethyl, etc.). Certain DOX compounds, such as the drug (R)-DOI, can be potent agonists of the serotonin 5-HT2 receptor. TIFF0007596296000016.tif51128
[0028] The binding affinity of DOX compounds to 5-HT2 receptors is typically in the low nanomolar range (e.g., 0.1-10 nM, Nichols, WIREs Membr. Transp. Signal 2012, 1:559-579, incorporated herein by reference), and is associated with a number of pathways that mediate 5-HT, such as the Gq pathway. 2A EC for effector pathway activation in receptors 50 The value of can be in the low nanomolar range (e.g., 1-10 nM, Figure 3).
[0029] The second class of compounds is referred to herein as "2Cx compounds" in reference to the absence of a side chain alpha methyl compared to the DOx class. Thus, the 2C side chain contains only two carbon atoms (2C). The binding affinity of 2CX compounds to the 5-HT2 receptor is typically in the nanomolar range (e.g., 1-10 nM, Johnson et al., Pharmacol. Biochem. Behav. 1990, 35(1):211-7, incorporated herein by reference), and inhibits 5-HT2 receptors, such as the G1 pathway. 2A EC for effector pathway activation at the receptor 50 The values of can be in the low nanomolar range (e.g., 1-10 nM), and they tend to exhibit lower potency than their DOx counterparts (Figure 3). TIFF0007596296000017.tif50128
[0030] The present invention provides 2C compounds where R is CH2CH(CH3)2 (formula (I)), CH2C(CH3)3 (formula (II)), or CH2CH(CH2)2 (formula (III)). TIFF0007596296000018.tif172128
[0031] The present invention relates, in part, to the fact that these 2C compounds inhibit the action of 5-HT 2A Based on the discovery that they can have high potency in activating receptors, high anti-inflammatory potency, but importantly, generally have low potency in affecting behavior compared to DOx compounds.Thus, the compounds disclosed herein can provide anti-inflammatory effects without inducing behavioral effects mediated by their action in the central nervous system (CNS).
[0032] Pharmaceutically acceptable acid addition salts of these compounds and their prodrugs are also disclosed herein.
[0033] II. Pharmaceutical Compositions. Pharmaceutical compositions of any of the aforementioned compounds (e.g., 2C compounds of formula (I), (II), or (III)) include tablets for oral use containing the compound in a mixture with non-toxic pharma- ceutically acceptable excipients, which may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch, including potato starch, sodium chloride, or lactose). Granulating and disintegrating agents (e.g., cellulose derivatives, including microcrystalline cellulose, starches, including potato starch, croscarmellose sodium, alginates, or alginic acid), binders (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol), and lubricants, glidants, and antiadherents (e.g., magnesium stearate, zinc stearate, stearic acid, silica, hydrogenated vegetable oil, or talc). Other pharma- ceutically acceptable excipients may be colorants, flavorings, plasticizers, humectants, buffers, and the like.
[0034] In some embodiments, a pharma- ceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved for human and veterinary use. In some embodiments, the excipient is approved by the U.S. Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.
[0035] In some embodiments, the pharmaceutical composition is prepared, packaged, and / or sold in a formulation suitable for pulmonary administration, for example, via the buccal cavity. Such formulations may include dry particles containing the active ingredient and having a diameter ranging from about 0.5 nm to about 7 nm or from about 1 nm to about 6 nm. Such compositions are conveniently in the form of a dry powder for administration using a device containing a dry powder reservoir capable of directing a stream of propellant to disperse the powder, and / or using a self-propelling solvent / powder dispensing container, such as a device containing the active ingredient dissolved and / or suspended in a low-boiling propellant in a closed container. Such powders include particles in which at least 98% of the particles by weight have a diameter greater than 0.5 nm and at least 95% of the particles by number have a diameter less than 7 nm. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nm and at least 90% of the particles by number have a diameter less than 6 nm. Dry powder compositions may include a solid fine powder diluent, such as sugar, and are conveniently provided in unit dosage form.
[0036] Low boiling point propellants generally include liquid propellants having a boiling point below 65° F. at atmospheric pressure. The propellant may comprise 50%-99.9% (w / w) of the composition, and the active ingredient may comprise 0.1%-20% (w / w) of the composition. The propellant may further comprise additional ingredients such as liquid non-ionic and / or solid anionic surfactants and / or solid diluents (which may have a particle size on the same order as the particles containing the active ingredient).
[0037] Pharmaceutical compositions formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and / or suspension. Such formulations may be prepared, packaged, and / or sold as aqueous and / or dilute alcoholic solutions and / or suspensions, optionally containing the active ingredient, in a sterile state, and may be conveniently administered using any nebulizer and / or atomizer device. Such formulations may further include one or more additional ingredients, including, but not limited to, flavoring agents such as sodium saccharin, volatile oils, buffers, surfactants, and / or preservatives such as methyl hydroxybenzoate. The droplets provided by this administration route may have an average diameter ranging from about 0.1 nm to about 200 nm.
[0038] The formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of pharmaceutical compositions.Another formulation suitable for intranasal administration is a coarse powder containing the active ingredient and having an average particle size of about 0.2 μm to 500 μm.Such formulations are administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal cavity from a container of powder held close to the nose.
[0039] Formulations suitable for nasal administration may, for example, contain from about 0.1% (w / w) to 100% (w / w) of the active ingredient, and may include one or more of the additional ingredients described herein. Pharmaceutical compositions may be prepared, packaged, and / or sold in a formulation suitable for pulmonary administration. Alternatively, formulations suitable for buccal administration may include powders, and / or aerosolized and / or atomized solutions, and / or suspensions containing the active ingredient. Such powders, aerosolized and / or aerosolized formulations, when dispersed, may have an average particle and / or droplet size in the range of about 0.1 nm to about 200 nm, and may further include one or more of any of the additional ingredients described herein.
[0040] The pharmaceutical composition may be in the form of tablets and / or lozenges prepared using conventional methods and may contain 0.1%-20% (w / w) of the active ingredient, the remainder being an orally soluble and / or degradable composition, and optionally one or more additional ingredients as described herein. The tablets may be uncoated or may be coated by known techniques, optionally to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. For example, the coating may be adapted to release the compound in a predetermined pattern (e.g., to achieve a controlled release formulation) or may be adapted not to release the compound until after passage through the stomach. The coating may be a sugar coating, a film coating (e.g., based on hydroxypropylmethylcellulose, methylcellulose, methylhydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycol and / or polyvinylpyrrolidone), or an enteric coating (e.g., based on methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and / or ethylcellulose). Additionally or alternatively, a time delay material, such as, for example, glyceryl monostearate or glyceryl distearate, can be incorporated into the tablet.
[0041] The solid tablet composition may include a coating adapted to protect the compound from undesired chemical changes (e.g., chemical degradation prior to release of the compound). Coatings may be applied to solid dosage forms similar to those described in the Encyclopedia of Pharmaceutical Technology (eds. J. Swarbrick and J.C. Boylan, 1988-1999, Marcel Dekker, New York).
[0042] The pharmaceutical composition for oral use can also be presented as a chewable tablet or as a hard gelatin capsule in which the compound is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium phosphate, or kaolin), or as a soft gelatin capsule in which the compound is mixed with water or an oil medium, e.g., peanut oil, liquid paraffin, or olive oil.Powder and granules can be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner, e.g., using a mixer, fluidized bed equipment, or spray drying equipment.
[0043] Powder, dispersible powder, or granules suitable for preparing aqueous suspension by adding water are convenient dosage forms for oral administration of compound. Formulation as suspension provides compound in a mixture with dispersing or wetting agent, suspending agent, and one or more preservatives. Suitable dispersing or wetting agents are, for example, naturally occurring phosphatides (e.g., lecithin or condensation products of ethylene oxide with fatty acid, long chain aliphatic alcohol, or partial ester derived from fatty acid) and hexitol or hexitol anhydride (e.g., polyoxyethylene stearate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monooleate, etc.). Suitable suspending agents are, for example, sodium carboxymethylcellulose, methylcellulose, sodium alginate, etc.
[0044] Pharmaceutical compositions can also be administered parenterally by injection, infusion or implantation (intravenous, intramuscular, subcutaneous, etc.) in dosage forms, formulations, or through suitable delivery devices or implants that contain conventional non-toxic pharmaceutically acceptable carriers and adjuvants.The formulation and preparation of such compositions are well known to those skilled in the art of pharmaceutical formulations.Formulations can be found in Hayes (Remington: The Science and Practice of Pharmacy, volume I and volume II. Twenty-second edition. Philadelphia, 2012).
[0045] Compositions for parenteral use (e.g., intravenous administration) may be provided in unit dosage form (e.g., single-dose ampoules) or in vials containing several doses and to which suitable preservatives may be added (see below). The composition may be in the form of a solution, suspension, emulsion, infusion device, or delivery device for implantation, or it may be presented as a dry powder to be reconstituted with water or other suitable vehicle before use. Apart from the compound (e.g., a compound having the structure of formula (I), (II), or (III)), the composition may include suitable parenterally acceptable carriers and / or excipients. The compound may be incorporated into microspheres, microcapsules, nanoparticles, liposomes, etc. for controlled release. In addition, the composition may include suspending agents, solubilizing agents, stabilizers, pH adjusters, and / or dispersing agents.
[0046] As indicated herein, the pharmaceutical compositions according to the present invention may be in a form suitable for sterile injection. To prepare such compositions, the compounds are dissolved or suspended in a parenterally acceptable liquid vehicle. Among the acceptable vehicles and solvents that may be used are water, water adjusted to a suitable pH by the addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution. Aqueous formulations may also contain one or more preservatives (e.g., methyl, ethyl, or n-propyl p-hydroxybenzoate). If one of the compounds is poorly soluble or only slightly soluble in water, a dissolution enhancer or solubilizer may be added, or the solvent may contain 10-60% w / w propylene glycol, or the like.
[0047] III. Method Provided herein is a method of using the compounds or pharmaceutical compositions described herein to treat inflammatory disorders in a subject. The method of treating inflammatory disorders comprises administering a therapeutically effective amount of the compounds or pharmaceutical compositions of the present invention to a subject in need thereof. For example, the method of treating inflammatory disorders comprises administering a compound of the present invention (e.g., a 2C compound having the structure of formula (I), (II), or (III), or an acid addition salt or prodrug thereof), or a pharmaceutical composition thereof. Alternatively, the method herein provides for the treatment of inflammatory disorders by administering such compounds or a pharmaceutical composition thereof.
[0048] The exact amount of compound or composition required for therapeutic effect may vary from subject to subject, depending on the species, age, weight, and general condition of the subject, the severity of the disease, the specific composition, its mode of administration, its mode of action, etc. Pharmaceutical compositions according to the present disclosure are typically formulated in dosage unit form for ease of administration and uniformity of dosage. However, it is understood that the total daily usage of the composition of the present disclosure will be determined by the attending physician within the scope of sound medical judgment. The specific therapeutically effective level for a particular subject will depend on a variety of factors, including the specific inflammatory disorder being treated and its severity, the activity of the specific compound being utilized, the specific composition being utilized, the subject's age, weight, general health, sex, and diet, the time of administration, the route of administration, and the excretion rate of the specific compound being utilized, the duration of treatment, drugs used in combination or simultaneously with the specific compound being utilized, and similar factors well known in the medical field.
[0049] In some embodiments of any of the methods described herein, the inflammatory disorder is asthma, chronic obstructive pulmonary disease, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, sepsis, or conjunctivitis.
[0050] The compositions described herein can be administered to a subject, such as a human patient, or other mammals, such as domesticated animals, cats, dogs, mice, or rats.
[0051] The compositions described herein can be administered by any route. In some embodiments, the compound or pharmaceutical composition thereof is administered by one or more of a variety of routes, including nasal, buccal, oral, inhalation (e.g., as oral spray, nasal spray, or aerosol), intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intracerebroventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (e.g., by powder, ointment, cream, gel, lotion, and / or drops), mucosal, intestinal, vitreous, intratumoral, sublingual, intratracheal instillation, bronchial instillation, and / or via portal vein catheter. In some embodiments, the composition is administered by systemic intravenous injection. In certain embodiments, the composition is administered intravenously and / or orally.
[0052] The compounds of the invention can be administered in a therapeutically effective amount (e.g., within a therapeutic window between a dose sufficient to reduce inflammation and a dose that induces a psychoactive effect, e.g., an amount that produces a desired therapeutic effect (about a 10-fold difference)). In some embodiments, the compounds can be administered in a therapeutically effective amount (e.g., an amount that produces a circulating drug plasma level of less than 20 ng / mL (e.g., 0.05-20 ng / mL, e.g., 0.1-15 ng / mL, 0.5-10 ng / mL, or 1-5 ng / mL, e.g., 0.05-0.1 ng / mL, 0.1-0.2 ng / mL, 0.2-0.3 ng / mL, 0.3-0.4 ng / mL, 0.4-0.5 ng / mL, 0.5- The compound is administered at a concentration of 1.0 ng / mL, 1.0-5 ng / mL, 5-10 ng / mL, 10-15 ng / mL, or 15-20 ng / mL, e.g., about 0.05 ng / mL, 0.1 ng / mL, 0.2 ng / mL, 0.5 ng / mL, 1.0 ng / mL, 2.0 ng / mL, 2.5 ng / mL, 5.0 ng / mL, 7.5 ng / mL, 10 ng / mL, 12 ng / mL, 15 ng / mL, or 20 ng / mL. In some embodiments, the circulating drug plasma levels of the compound are below the limit of detection (e.g., below 0.1 ng / mL). In some embodiments, the therapeutically effective amount of the compound may be less than about 20 μg / kg body weight (e.g., less than 20 μg / kg, less than 15 μg / kg, less than 10 μg / kg, or less than 5 μg / kg body weight, e.g., 1-20 μg / kg body weight, e.g., 1-5 μg / kg, 5-10 μg / kg, 10-15 μg / kg, or 15-10 μg / kg, e.g., about 5 μg / kg, about 10 μg / kg, about 15 μg / kg, or about 20 μg / kg).
[0053] In certain embodiments, compositions according to the present disclosure may be administered one or more times per day at a dosage level sufficient to deliver about 0.0001 μg / kg to about 100 μg / kg, about 0.01 μg / kg to about 50 μg / kg, about 0.1 μg / kg to about 40 μg / kg, about 0.5 μg / kg to about 30 μg / kg, about 0.01 μg / kg to about 10 μg / kg, about 0.1 μg / kg to about 10 μg / kg, or about 1 μg / kg to about 25 μg / kg of subject body weight per day to obtain the desired therapeutic effect. The desired dosage may be delivered three times per day, twice per day, once per day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In some embodiments, the compound is administered one to three times per week (e.g., once per week, twice per week, three times per week, four times per week, five times per week, six times per week, seven times per week, or more, e.g., once per day, twice per day, three times per day, etc.). In some embodiments, the compound is administered intermittently, e.g., every other day, every other week, once per month, etc. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more administrations).
[0054] The compositions described herein can be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents. By "in combination with," it is not intended that the agents must be administered simultaneously and / or formulated to be delivered together, although these delivery methods are within the scope of the present disclosure. The pharmaceutical compositions can be administered simultaneously with, prior to, or after one or more other desired treatments or medical procedures. In general, each agent is administered at a dose and / or time schedule determined for that agent. In some embodiments, the present disclosure encompasses the delivery of pharmaceutical, prophylactic, diagnostic, or imaging compositions in combination with agents that improve their bioavailability, reduce and / or modify their metabolism, inhibit their excretion, and / or modify their distribution within the body.
[0055] It is further understood that the compounds or compositions utilized in combination can be administered together in a single composition or can be administered separately in different compositions.In general, it is expected that the agents utilized in combination will be utilized at levels that do not exceed the levels that they are utilized individually.In some embodiments, the levels utilized in combination are lower than the levels that they are utilized individually. EXAMPLES
[0056] The following examples are presented to provide one of ordinary skill in the art with an understanding of how to make, prepare, and evaluate the compositions and methods claimed herein, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.
[0057] Example 1. Synthesis and characterization of 2C-iBu The synthesis of 2C-iBu is a modification of the synthetic route for DOiBu described in Oberlender et al., J. Med. Chem. 1984, 27(6), 788-792, which is incorporated herein by reference. Briefly, aldehyde 10 was treated with nitromethane and ammonium acetate to give the corresponding nitroethene as bright yellow needle-like crystals. Reduction of the nitroethene with a solution of LiAlH4 and standard workup produced the amine, which was converted to the hydrochloride salt and crystallized. The synthetic route is shown in Figure 1A.
[0058] The purity of 2C-iBu was assessed using LCUV and LCMS analysis. A 10 mM stock solution of 2C-iBu in DMSO was diluted to 200 μM with 25% methanol / 25% acetonitrile / 50% H2O. A blank sample was prepared by diluting an equal volume of DMSO in the same manner.
[0059] Diluted samples of 2C-iBu were analyzed by LCUV and LCMS using the following method. LCUV Mobile phase A: 12 mM ammonium formate / 6 mM formic acid in water Mobile phase B: 6 mM ammonium formate / 3 mM formic acid in water / acetonitrile (1 / 9, v / v) Column: Thermo DASH aQ C18, 3 micron, 2.1 x 20 mm (#25003-022150) Gradient program: (Table 1) TIFF0007596296000019.tif41128Detection by Dionex UltiMate3000 diode array detector Wavelength:UV-Vis_1:205nm+ / -10nm UV-Vis_2: 230nm+ / -10nm UV-Vis_3: 260nm+ / -10nm UV-Vis_4: 300nm+ / -10nm LCMS Mobile phase A: 0.1% formic acid in water Mobile phase B: 0.1% formic acid in acetonitrile Column: Acquity HSS T3, 1.8 micron, 2.1 x 100 mm (#186003539) Gradient program: (Table 2) TIFF0007596296000020.tif47128Detection by Xevo G2 QTof (Waters) mass spectrometer Acquisition method: Positive, Sensitivity mode, MS E Source temperature: 150℃ Desolvation temperature: 475℃ Capillary voltage: 1.5kV Sampling cone voltage: 125V Extraction cone voltage: 7.0V Cone gas: 100L / h Desolvation gas: 500L / h Mass range: 100-1000 Da
[0060] Figure 1B shows a single primary peak eluting at 1.1 min. One small additional peak eluting at 1.27 min was visible in the 2C-iBu chromatogram and was not observed in the blank sample, however, LCMS analysis did not show any significant analytes eluting later than the parent in the chromatogram.
[0061] As shown in Figure 1C, an early eluting peak at 4.11 min was observed in the LCMS chromatogram with an ion at 219 m / z in the mass spectrum. The parent compound has an abundant precursor ion at 221 m / z, likely arising from loss of an amino group in the MS source. The peak at 4.11 min likely represents an impurity that fragments in the same way, 2 mass units less than the parent compound. In conclusion, 2C-iBu is greater than 99% pure within the detection limits of the method used in this study.
[0062] Example 2. Receptor Pharmacology Stable human 5-HT 2A HEK cells expressing the receptor (Braden et al., Mol. Pharmacol. 2006, 70(6):1956-1964, incorporated herein by reference) were assayed for Gq-mediated calcium transients induced by 2C-iBu (Table 3) and other compounds (Figure 3). 50 and E MAXThe values were used to determine the chromatin concentration. Cells were seeded in 96-well poly-D-lysine plates at approximately 50,000 cells / well 24 h before the experiment and cultured at 37 °C in Opti-MEM reduced serum medium supplemented with 4% dialyzed fetal bovine serum. On the day of the experiment, cells were washed once with HBSS supplemented with 20 mM HEPES, loaded with 75 μL of 3 μM Fluo-4AM (Molecular Probes) diluted in HBSS-HEPES buffer, incubated for 1.5 h at room temperature, washed twice with HBSS-HEPES, and maintained in 50 μL of HBSS-HEPES at 25 °C. The plate of dye-loaded cells was placed in a FlexStation III microplate reader (Molecular Devices, LLC) and fluorescence (excitation, 488 nm; emission, 525 nm; cutoff, 515 nm) was monitored. Test compounds were added at 2x concentration in 50 μL of HBSS-HEPES 30 s after the start of the scan, and fluorescence was monitored for an additional 200 s at 2 s intervals. After acquiring calcium mobilization traces for each sample, calcium responses for test compounds were quantified as the percentage change (peak fluorescence - baseline fluorescence level, denoted as ΔF) from baseline fluorescence level (denoted as F). ΔF / F (%). As a control, the buffer-only signal constituted the baseline response, and the peak signal of the serotonin agonist constituted the 100% response. Bar graphs and curve fitting routines were performed using Graph-Pad Prism 3.0 (GraphPad Software, Inc.).
[0063] To measure β-arrestin-2 recruitment by 2C-IBU, HTLA cells were incubated with 5-HT 2A Transiently transfected with R-Tango constructs, as described in (Nat. Struct. Mol. Biol. 2015, 22:362-369, incorporated herein by reference), PRESTO-Tango recruitment assays were then performed by measuring luminescence as described by Kroeze et al. 50 and E max The values were determined and the results are shown in Table 3 below.
[0064] Table 3. Summary of receptor pharmacology TIFF0007596296000021.tif27128
[0065] Head-to-head comparison of DOx vs. 2C compounds Using the methods described above, 2C compounds were directly compared to DOx compounds with respect to calcium mobilization and beta-arrestin recruitment. Data are presented as E as a percentage of the 5-HT response. MAX , and pEC 50 The results are shown in Tables 4 and 5 below.
[0066] Table 4: Calcium mobilization TIFF0007596296000022.tif54128
[0067] Table 5. Beta-arrestin recruitment TIFF0007596296000023.tif54128 * No activity detected
[0068] Example 3. Allergic asthma model A modification of the ovalbumin model of allergic asthma and whole-body plethysmography protocol as described by Nau et al. (Am. J. Physiol. Lung Cell Mol. Physiol. 2015, 308(2):L191-L198, incorporated herein by reference) was used to determine ΔPenh, a measure of airway hyperresponsiveness (AHR), in response to methacholine challenge in adult male Brown Norway rats. Results shown in Figures 2A-2G represent PenH changes measured in the rat ovalbumin allergic asthma assay, except for Figure 2C, which was measured in mice for nebulized inhaled drugs. Statistics were performed using a two-way ANOVA with Tukey post-hoc test for multiple comparisons.
[0069] Allergic asthma is defined as a chronic inflammatory disorder of the airways. The disease is characterized by airway inflammation, persistent airway AHR, and intermittent, reversible airway obstruction. Chronic allergen exposure in rodents has been shown to recapitulate some of the hallmarks of asthma, including allergen-dependent sensitization, Th2-dependent allergic inflammation characterized by eosinophil influx into the airway mucosa, and AHR.
[0070] As shown in Figure 2A, treatment with (R)-DOI demonstrated full efficacy in preventing AHR, as measured by PenH, in rats in response to the allergen OVA. There is no statistical difference between PenH values between the naive (blue line) and (R)-DOI+OVA (red line) groups. As shown in Figure 2B, 25I-NBOMe, which contains modifications of the amino group compared to R-DOI, showed reduced potency. Although 25I-NBOMe reduced PenH, PenH was significantly elevated above the naive control. As shown in Figure 2C, changing the iodine at the 4-position in R-DOI to a bromine (thereby obtaining DOB) did not reduce potency. However, cyclization of the 2,5,dimethoxy and removal of the alpha carbon reduced potency (Figure 2D), as did cyclization and rigidification of the side chain to obtain TCB-2 (Figure 2E). TCB-2 reduced PenH, but it was still significantly elevated above naive controls. As shown in Figure 2F, replacement of the 4-position with trifluoromethyl resulted in loss of potency. There was no statistical difference between the OVA and drug+OVA groups with respect to PenH values. Figure 2G shows that removal of the alpha carbon and placement of an isobutyl at the 4-position to obtain 2C-iBu did not result in a decrease in potency compared to (R)-DOI. This result represents a fully effective anti-inflammatory effect to block bronchial inflammation that would otherwise have induced an increased response to methacholine.
[0071] A summary of the efficacy of various DOx and 2Cx compounds at a 0.5 mg / kg dose in rats in preventing AHR is provided in Figure 3. The area under the curve for PenH values in response to increasing doses of methacholine (PenH-AUC) was calculated for each test group of naive, OVA-treated, and OVA + drug-treated animals. A reduction in PenH-AUC values of more than 75% of the control value (OVA only) was annotated as strong efficacy. Moderate efficacy was 25-75% inhibition, and less than 25% inhibition was annotated as inactive. In addition to this information, the 5-HT 2A RR-DOI EC of compounds tested in heterologous cell-based calcium transient assay 50 Relative values (ratios) are provided. Additionally, estimated ratios of psychoactive doses in humans for each compound compared to the R-DOI are provided. Figure 3 shows the non-correlation of therapeutic efficacy of compounds of the phenylethylamine class on inflammation-mediated allergen-induced AHR, as well as reported evidence of doses required for psychoactive impairment experienced with these compounds in humans, or 5-HT in calcium transient assays. 2A The efficacy and potency of these compounds against R.
[0072] Inhibition of ΔPenh as a function of 2C-iBu concentration was studied by nose-only administration of aerosolized 2C-iBu to adult male Brown Norway rats, as described above. The results are shown in Figure 4. The area under the curve for ΔPenh for each treatment group at a given dose of 2C-iBu is plotted on the Y-axis against the concentration of 2C-iBu on the X-axis. ED 50 was 0.0027 mg / kg, which was comparable to (R)-DOI. In summary, the results shown in this example indicate that 2C-iBu exhibits similar efficacy to (R)-DOI.
[0073] Example 4. Behavioral studies Head twitch response (HTR) is a response to hallucinogens and non-hallucinogens containing 5-HT. 2AThe HTR can reliably discriminate between 5-HT receptor agonists and can therefore be used as a behavioral surrogate in rodents for the effects of hallucinogens in humans. Similar to the discriminative stimulus effects of hallucinogens, the HTR inhibits the 5-HT 2A 5-HT serves as a behavioral readout of activation 2A It can be used to compare the in vivo potency of receptor agonists. HTR studies were performed with (R)-DOI and 2C-iBu in C57BL / 6J mice.
[0074] material and method To obtain the results reported in this example, the following methods were used.
[0075] animal Male C57BL / 6J mice (6–8 weeks old) obtained from Jackson Laboratories (Bar Harbor, ME, USA) were housed up to four per cage in a temperature-controlled room with a reverse light cycle (lights on at 1900 h, off at 0700 h) and provided free access to food and water, except during behavioral testing. Testing was performed between 1000 and 1800 h.
[0076] Drugs Drug doses are based on equivalent free base weight. Test substances were dissolved in sterile isotonic saline and injected subcutaneously (SC) at a volume of 5 mL / kg.
[0077] Head twitch response research HTR was assessed using a head-mounted magnet and magnetometer detection coil according to known methods. Briefly, mice were anesthetized, a small incision was made in the scalp, and a small neodymium magnet was attached to the dorsal side of the skull using dental cement. After a 2-week recovery period, HTR experiments were performed in a well-lit room with at least 7 days between sessions to avoid carryover effects. Test compounds were injected immediately prior to testing. Mice were injected with drug or vehicle, and then HTR activity was recorded inside a glass cylinder surrounded by a magnetometer coil. Coil voltages were low-pass filtered (2–10 kHz cutoff frequency), amplified, and digitized (20 kHz sampling rate) and then offline filtered (40–200 Hz bandpass) using a Powerlab / 8SP with LabChart v 7.3.2 (ADInstruments, Colorado Springs, CO, USA). Head twitches were manually identified based on the following criteria: 1) sinusoidal wave, 2) evidence of at least three consecutive head movements (usually manifested as a bipolar peak) with a frequency of 40 Hz or greater, 3) amplitude above the level of background noise, 4) duration <0.15 s, and 5) stable coil voltage immediately before and after each response.
[0078] Experimental design and data analysis Experiment 1. Five groups of mice (n=6 / group, 30 in total) were treated with vehicle or R-DOI (0.1, 0.3, 1, or 3 mg / kg) and HTR activity was assessed for 30 min. Experiment 2. Five groups of mice (n=6-7 / group, 34 in total) were treated with vehicle or 2C-iBu (0.3, 1, 3, or 10 mg / kg) and HTR activity was assessed for 30 min. Experiment 3. Two groups of mice (n=7 / group, 14 in total) were treated with R-DOI (1 mg / kg) or 2C-iBu (3 mg / kg) and HTR activity was assessed for 210 min.
[0079] In experiments 1 and 2, head twitches were examined throughout the entire 30-min recordings, and head twitch counts were analyzed using one-way analysis of variance (ANOVA). Additionally, HTR counts were analyzed in 2-min time blocks using one-way ANOVA, with time as the repeated measure. Post-hoc pairwise comparisons between selected groups were performed using Tukey's Studentized Range method. Significance was demonstrated by exceeding an alpha level of 0.05.
[0080] Median effective dose (ED 50 Values and 95% confidence intervals (95% CI) were calculated by nonlinear regression (Prism 7.00, GraphPad Software, San Diego, CA, USA). A Gaussian distribution was used to fit the biphasic HTR dose-response data. In these equations, E is the effect of the drug, Baseline is the response of the control group, Range is the distance from the baseline to the top of the curve, [A] is the dose of the drug, and A is the logarithm of the dose that corresponds to the top of the curve. To determine whether potency differences exist between individual compounds, an extra-sum-of-squares F-test was used to measure the ED 50 Values were compared, and significance was demonstrated by exceeding an alpha level of 0.05.
[0081] In experiment 3, HTR counts were examined in 5-min time blocks. A monophasic exponential decay function was fitted to the descending phase of the data to determine the half-life of the drug response. Responses produced by R-(-)-DOI (1 mg / kg) or ELEU02 were analyzed using one-way ANOVA, with time as the repeated measure. Post-hoc pairwise comparisons between groups were performed using Sidak's multiple comparison test. Significance was demonstrated by exceeding an alpha level of 0.05.
[0082] result Experiment 1 Table 6: HTR induced by R-DOI TIFF0007596296000025.tif41128**p<0.01 vs. vehicle control, Tukey's test.
[0083] Administration of R-DOI produced a dose-dependent increase in HTR counts (F(4,25)=13.70, p<0.0001, Figure 5A and Table 6). HTRs induced by R-DOI followed an inverted U-shaped dose-response function, with a peak response occurring after administration of 1 mg / kg (128.0±13.2 [mean±SEM] counts / 30 min).
[0084] R-DOI is 50 induced an HTR of 0.20 (95% CI 0.11-0.35) mg / kg. Based on molar mass, the ED 50 The ED was 0.63 (95% CI 0.35-1.10) μmol / kg. Interestingly, when R-(-)-DOI was administered IP under otherwise identical experimental conditions, 50 The ED using the F-test of the extra squares was 0.66 (95% CI 0.47-0.93) μmol / kg HTR. 50 Comparison of the values confirmed that the efficacy of R-DOI was not significantly affected by its route of administration (F(1,52) = 0.03, P = 0.87).
[0085] Responses to the R-DOI were also analyzed in 2-min time blocks. As shown in Figure 5B, responses to the R-DOI were time-dependent (drug × time: F(56,350) = 2.93, p < 0.0001). The interval between injection and maximal effect was inversely proportional to the dose of R-DOI. Maximal responses occurred 24-26 min after administration of 0.3 mg / kg, 4-6 min after administration of 1 mg / kg, and 2-4 min after administration of 3 mg / kg.
[0086] Experiment 2 Table 7. HTR induced by 2C-iBu TIFF0007596296000026.tif41128*p<0.05, **p<0.01 vs. vehicle control, Tukey's test.
[0087] Administration of 2C-iBu produced a dose-dependent increase in HTR counts (F(4,29)=28.36, p<0.0001, Figure 6A). Similar to R-DOI, HTR induced by 2C-iBu followed an inverted U-shaped dose-response function, with a peak response occurring after administration of 3 mg / kg (111.1±4.7 counts / 30 min).
[0088] 2C-iBu is an ED 50 induced an HTR of 0.70 (95% CI 0.52-0.93) mg / kg. Based on molar mass, the ED 50 was 2.17 (95% CI 1.63-2.89) μmol / kg, which means that it was approximately one-third as potent as R-DOI. An F-test of the extra-sum-of-squares confirmed that 2C-iBu was significantly less potent than R-DOI (F(1,58)=12.92, p=0.0007).
[0089] Responses to 2C-iBu were also analyzed in 2 min time blocks. As illustrated in Figure 6B, responses to 2C-iBu were time-dependent (drug × time: F(56,406) = 3.80, p < 0.0001). The interval between injection and maximal effect was inversely proportional to the dose of 2C-iBu. Maximal responses occurred 24-28 min after administration of 1 mg / kg, 18-24 min after administration of 3 mg / kg, and 2-4 min after administration of 10 mg / kg.
[0090] Experiment 3 We next characterized the time course of responses produced by R-DOI and 2C-iBu. For this experiment, mice were treated with maximally effective doses of R-DOI (1 mg / kg SC) and 2C-iBu (3 mg / kg SC) and HTR activity was monitored continuously for 210 min.
[0091] The HTR induced by 1 mg / kg R-DOI peaked 5–10 min after administration (23.3 ± 3.5 counts / 5 min) and then gradually decreased over the remainder of the test session (Figure 7). Fitting the post-peak data with a one-phase exponential decay function yielded a half-life of the response of 84.64 min (95% CI: 77.65–93.0 min; r 2 =0.684).
[0092] The HTR induced by 3 mg / kg 2C-iBu peaked 20–25 min after administration (20.1 ± 3.5 counts / 5 min) and then gradually decreased over the remainder of the test session (Figure 7). Fitting the post-peak data with a one-phase exponential decay function yielded a half-life of the response of 111.4 min (95% CI: 100.1–125.4 min; r 2 =0.5709).
[0093] In addition to analyzing the time course of responses produced by R-DOI and 2C-iBu, we also directly compared their effects. There was no main effect of drug treatment (F(1,12)=0.33, p=0.58), but there was a main effect of time (F(41,192)=39.55, p<0.0001) and a significant interaction between drug treatment and time (F(41,492)=4.36, p<0.0001). Post-hoc pairwise comparisons showed that there was a significant difference only between the effects of R-DOI and 2C-iBu during the first and second 5-min time blocks (p<0.0001, Sidak's multiple comparison test).
[0094] These data suggest that 2C-iBu inhibits 5-HT 2AExample 3 demonstrates that 2C-iBu was approximately 3-fold less potent than R-DOI in inducing head twitch responses in a rodent model of receptor-mediated psychoactivity. Furthermore, 2C-iBu demonstrated a significant delay in the time to peak response in inducing head twitch behavior compared to R-DOI. On the other hand, Example 3 demonstrated that the therapeutic efficacy of 2C-iBu was similar to R-DOI in reducing AHR in a rodent asthmatic inflammation model. Thus, although 2C-iBu retains therapeutic properties of interest in disease models of inflammation, these results indicate that this compound does not share the same tendency as R-DOI in inducing undesirable psychoactive effects.
[0095] Example 5. 5-HT Receptor Binding Studies This example describes the testing of R-DOI and 2C-iBu in binding assays of various 5-HT receptors. Radioligand binding was assessed at equilibrium using the ligands shown in Table 8 on recombinantly expressed human receptors from membrane preparations using standard conditions in Cerep Eurofins Discovery and gold standard filtration methods according to generally accepted methodologies as described in Auld et al. (Receptor Binding Assays for HTS and Drug Discovery. 2012. In: Sittampalam et al., editors. Assay Guidance Manual [Internet], Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004). Each test compound was titrated and tested at several concentrations under competitive binding conditions to determine the half maximal inhibitory concentration (IC50) and its apparent binding affinity (equilibrium dissociation constant (Ki)). IC50 values (concentration causing half-maximal inhibition of control specific binding) and Hill coefficients (nH) were determined by nonlinear regression analysis of the competition curves generated with the average replicate values using Hill equation curve fitting. This analysis was performed using software developed at Cerep (Hill software) and was verified by comparison with data generated by the commercial software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). Inhibitory constants (Ki) were calculated using the Cheng Prusoff equation. pKi values were calculated as the negative logarithm to the base 10 of the equilibrium dissociation constant, Ki in molar units, and are listed in Table 8 below. Table 9 shows examples of pIC50 of one reference ligand for each receptor tested under generally similar experimental conditions. In general, the pKi values of both test compounds indicate a higher affinity for their primary or co-primary receptor target than the endogenous ligand, serotonin.The specificity of R-DOI with respect to apparent affinity to the 5-HT receptor was _2A>_2C>_2B>>_1A=_1B. The specificity of 2C-iBu with respect to apparent affinity to the 5-HT receptor was _2C>_2A>_2B>_1A=_1B=_1C>_7>_6.
[0096] (Table 8) TIFF0007596296000027.tif53137
[0097] (Table 9) TIFF0007596296000028.tif53128
[0098] Example 6. Toxicity studies of R-DOI and 2C-ibu In vitro protein binding, absorption, and microsome-specific clearance studies were performed to compare a number of in vitro ADME / tox metrics between R-DOI and 2C-iBu. Each assay was standardized and the methods were validated to meet the acceptance criteria for non-GLP studies in drug development and to follow commonly accepted methodologies as described in Chung et al. (In Vitro and In Vivo Assessment of ADME and PK Properties During Lead Selection and Lead Optimization-Guidelines, Benchmarks and Rules of Thumb. 2015; In: Sittampalam et al. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004).
[0099] In vitro protein binding assays were performed using test compounds (R-DOI or 2C-iBu) in human plasma. R-DOI and 2C-iBu were each 1.0 × 10 -5Concentrations of M were tested. The results are shown in Table 10 below.
[0100] Table 10. Protein binding assay results TIFF0007596296000029.tif25163
[0101] In vitro absorption assays were performed using test compounds (R-DOI or 2C-iBu) incubated with Caco-2 cells at pH 6.5 / 7.4. R-DOI and 2C-iBu were each administered at 1.0 × 10 -5 Concentrations of M were tested. The results are shown in Table 11 below.
[0102] Table 11. Absorption assay results TIFF0007596296000030.tif48163
[0103] In vitro metabolic assays were performed to test for intrinsic clearance using test compounds (R-DOI or 2C-iBu) incubated with human liver microsomes for various times (0, 15, 30, 45, and 60 min). R-DOI and 2C-iBu were each incubated at 1.0 × 10 -7 The compounds were tested at concentrations of M. The results are shown in Table 12 below.
[0104] Table 12. In vitro metabolism results TIFF0007596296000031.tif71163
[0105] In general, both compounds were fully soluble at the maximum tested concentration of 200 micromolar in PBS and simulated intestinal fluid aqueous environment. 2C-iBu showed a decreased hydrophilic profile compared to R-DOI, with an increased logD at physiological pH from 1.04 for R-DOI to 1.64 for 2C-iBu. This difference in physicochemical properties may be one of the driving forces for the observed increased plasma protein binding capacity of 2Ci-Bu compared to the modest changes in R-DOI and Caco-2 AB / BA permeability profiles. Both R-DOI and 2C-iBu were metabolically stable compounds, with Clints below 115.5 in the human liver microsomal intrinsic clearance assay.
[0106] Example 7. Proof-of-concept study for the treatment of inflammatory arthritis Collagen-induced arthritis is an animal model of human rheumatoid arthritis. Mice are immunized with type II collagen (CII) (e.g., bovine CII). This model recapitulates many of the innate and adaptive immune mechanisms that characterize human rheumatoid arthritis and has been used to test therapeutics subsequently developed as human treatments.
[0107] Arthritis is induced in C57 / Bl6 mice in three steps: mice are immunized with bovine CII in complete Freund's adjuvant, administered subcutaneously (sc), on day 0. A second immunization with CII suspended in incomplete Freund's adjuvant is administered sc on day 21. Finally, on day 24, 25 μg of lipopolysaccharide is administered via intraperitoneal injection.
[0108] Mice are dosed twice weekly via tail vein injection of 2C compound at a dose confirmed to be non-behaviorally potent, for example, at the dose and frequency administered according to the methods described herein. Control mice are not immunized with CII and receive no treatment or placebo. Treatment begins after 10% to 30% of the mice develop arthritis.
[0109] Mice are assessed by daily cumulative disease scores. Mice are weighed once or twice weekly and paw thickness is measured twice weekly for the first 3 weeks. Blood, lymph nodes, spleens, and joints are harvested for histopathology and immunological analysis, including titers of anti-CII antibodies in the blood, and other inflammatory markers expressed by cells and circulating in the blood, such as inflammatory cytokines.
[0110] Mice receiving 2C compound have lower cumulative scores, less frequent arthritic limbs, and lower average paw thickness compared to control mice. Mice receiving 2C compound also have lower levels of anti-CII antibodies (e.g., IgG2a), and proinflammatory markers such as activated immune cells and circulating inflammatory cytokines compared to control mice.
[0111] Example 8. Proof-of-concept study for the treatment of multiple sclerosis Experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis that shares many pathogenic underpinnings with a wide range of autoimmune diseases. In this example, we summarize the treatment of EAE with 2C compound.
[0112] EAE was initiated with 200 μg MOG in complete Freund's adjuvant. 35-55 In addition, 200 ng of pertussis toxin is administered intraperitoneally (ip) on days 0 and 2.
[0113] 2C compounds are administered intravenously at an amount and frequency confirmed to be non-behaviorally potent, for example, using any of the methods described herein. Mice are monitored daily for clinical signs of EAE starting on day 10 and continuing through day 24. EAE is scored as follows: 0, no signs of disease; 1, loss of tail tone; 2, hind limb paresis; 3, hind limb paralysis; 4, quadriplegia; and 5, moribund. The average score is calculated for each group of mice. At the end of the experiment, brains, lymph nodes, and spleens are harvested and the following experiments are performed to evaluate the immunological effects of 2C compounds.
[0114] Spleens were dissociated into single cell suspensions and incubated with MOG at concentrations of 1, 10, or 100 μg / mL. 35-55 Immune recall is measured following stimulation with peptides. Cell proliferation is measured after 72 hours using the MTT cell proliferation assay. Brains and spinal cords are harvested and dissociated into single cell suspensions. T cells are isolated using magnetic beads, stained with antibodies against interleukin 17 (IL-17) and interferon gamma (IFNγ), and analyzed by flow cytometry.
[0115] Mice administered sub-behavioral doses of 2C compound exhibited reduced MOG expression compared to control mice, as characterized, for example, by reduced cell proliferation using the MTT assay. 35-55 T cells from brain and spinal cord tissue of mice receiving subbehavioral doses of 2C compound express less inflammatory markers, such as IL-17 and IFNγ, compared to control mice.
[0116] Other embodiments All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0117] While the invention has been described in relation to particular embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention which generally follow the principles of the invention and which the invention pertains to and can be applied to the essential features described above, including such departures from the present disclosure which are within known or customary practice in the art which follows the claims.
[0118] Other embodiments are within the scope of the claims.
Claims
1. Compounds of formula (I) or a pharma- ceutically acceptable acid addition salt thereof.
2. 13. A pharmaceutical composition comprising a compound of claim 1 and a pharma- ceutically acceptable excipient.
3. 3. The pharmaceutical composition of claim 2, formulated for oral, intranasal, or pulmonary administration.
4. 13. A pharmaceutical composition for treating an inflammatory disorder in a subject in need thereof, comprising a therapeutically effective amount of a compound of claim 1.
5. 5. The pharmaceutical composition of claim 4, wherein the compound is administered in an amount of less than 20 μg / kg body weight.
6. The pharmaceutical composition according to claim 4 or 5, which is administered at a frequency of 1 to 3 times a week.
7. 7. The pharmaceutical composition of any one of claims 4 to 6, wherein the inflammatory disorder is selected from the group consisting of asthma, chronic obstructive pulmonary disease, neuroinflammation, rheumatoid arthritis, atherosclerosis, psoriasis, type II diabetes, inflammatory bowel disease, Crohn's disease, multiple sclerosis, sepsis, and conjunctivitis.
8. The pharmaceutical composition according to any one of claims 4 to 7, which is administered orally, intranasally or by inhalation.
Citation Information
Patent Citations
Antiparkinsonian Action of Phenylisopropylamines
US20150025063A1
Low dosage serotonin 5-HT2a receptor agonist to suppress inflammation
US20180055791A1
Preparation of desiccated liposomes for use in compressible delivery systems
WO2014028796A2
Compositions and methods to reduce pathogenesis
WO2018204354A1
Use of cannabidiol in combination with 5-HT2b receptor agonists or amphetamins in the treatment of epilepsy
WO2019064031A1
